126 related articles for article (PubMed ID: 36697087)
1. Small Bowel Lipomatosis: An Unusual Radiological Finding in Patients With Renal Cell Cancer on Pazopanib.
Sharma A; Lakhani A; Ghosh-Ray S; Alam S; Padhani A; Gogbashian A; Nathan P
Anticancer Res; 2023 Feb; 43(2):789-793. PubMed ID: 36697087
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibitor-induced immune hemolytic anemia; three different drugs in three separate cases.
Güzel HG; Kıvrak Salim D
J Oncol Pharm Pract; 2024 Jan; 30(1):215-219. PubMed ID: 37724017
[TBL] [Abstract][Full Text] [Related]
3. Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors.
Tahiri A; Puco K; Naji F; Kristensen VN; Alfsen GC; Farkas L; Nilsen FS; Müller S; Oldenburg J; Geisler J
Oncotarget; 2022; 13():970-981. PubMed ID: 36093296
[TBL] [Abstract][Full Text] [Related]
4. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
Pal SK; Jonasch E; Signorovitch JE; Reichmann WM; Li N; Liu Z; Perez JR; Vogelzang NJ
J Med Econ; 2016; 19(5):462-8. PubMed ID: 26652893
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population.
Isaacsson Velho P; Nardo M; Souza MCLA; Bonadio RRCC; Marta GN; Muniz DQB; Bastos DA; Dzik C
J Glob Oncol; 2018 Aug; 4():1-10. PubMed ID: 30199304
[TBL] [Abstract][Full Text] [Related]
6. Lost in third space: altered tyrosine-kinase inhibitor pharmacokinetics in a patient with malignant ascites.
Krens SD; Mulder SF; van Erp NP
Cancer Chemother Pharmacol; 2022 Feb; 89(2):271-274. PubMed ID: 34853912
[TBL] [Abstract][Full Text] [Related]
7. Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience.
Topal A; Sayın S; Gokyer A; Kucukarda A; Kostek O; Bekir Hacıoglu M; Uzunoglu S; Erdogan B; Cicin I
J BUON; 2021; 26(4):1628-1634. PubMed ID: 34565028
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety.
Amaro F; Pisoeiro C; Valente MJ; Bastos ML; Guedes de Pinho P; Carvalho M; Pinto J
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077297
[TBL] [Abstract][Full Text] [Related]
9. TOKIO rationale and protocol: a phase II study to evaluate the activity and safety of third-line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.
Verzoni E; Grassi P; Montone R; Galli G; Necchi A; Procopio G
Tumori; 2015; 101(6):701-3. PubMed ID: 26108242
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation.
Ranieri G; Marech I; Niccoli Asabella A; Di Palo A; Porcelli M; Lavelli V; Rubini G; Ferrari C; Gadaleta CD
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28891933
[TBL] [Abstract][Full Text] [Related]
11. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.
Keisner SV; Shah SR
Drugs; 2011 Mar; 71(4):443-54. PubMed ID: 21395357
[TBL] [Abstract][Full Text] [Related]
12. Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era.
Bellmunt J; Esteban E; Del Muro XG; Sepúlveda JM; Maroto P; Gallardo E; Del Alba AG; Etxaniz O; Guix M; Larriba JLG; Arranz JA; Redrado M; Calvo A
Eur Urol Oncol; 2021 Jun; 4(3):502-505. PubMed ID: 31477526
[TBL] [Abstract][Full Text] [Related]
13. Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib.
Demircan NC; Alan Ö; Başoğlu Tüylü T; Akın Telli T; Arıkan R; Çiçek FC; Ercelep Ö; Öztürk MA; Alsan Çetin İ; Ergelen R; Tinay İ; Akgül Babacan N; Kaya S; Dane F; Yumuk PF
J Oncol Pharm Pract; 2020 Jul; 26(5):1147-1155. PubMed ID: 31793376
[TBL] [Abstract][Full Text] [Related]
14. Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis.
Deng H; Huang Y; Hong Z; Yuan X; Cao Z; Wei Y; Zhang W
BMC Cancer; 2019 May; 19(1):489. PubMed ID: 31122210
[TBL] [Abstract][Full Text] [Related]
15. Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis.
Liu Y; Zhou L; Chen Y; Liao B; Ye D; Wang K; Li H
BMC Urol; 2019 Jun; 19(1):49. PubMed ID: 31174518
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
Vogelzang NJ; Pal SK; Signorovitch JE; Reichmann WM; Li N; Yang C; Liu Z; Perez JR; Jonasch E
Curr Med Res Opin; 2016; 32(4):741-7. PubMed ID: 26744781
[TBL] [Abstract][Full Text] [Related]
17. The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review.
Sneed GT; Lee S; Brown JN; Hammond JM
Clin Genitourin Cancer; 2019 Dec; 17(6):419-424. PubMed ID: 31585694
[TBL] [Abstract][Full Text] [Related]
18. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
Daimon M; Kato T; Kaino W; Takase K; Karasawa S; Wada K; Kameda W; Susa S; Oizumi T; Tomita Y; Kato T
Jpn J Clin Oncol; 2012 Aug; 42(8):742-7. PubMed ID: 22628612
[TBL] [Abstract][Full Text] [Related]
19. [Interdisciplinary recommendations for the treatment of advanced metastatic renal cell carcinoma].
Miller K; Bergmann L; Doehn C; Grünwald V; Gschwend JE; Ivanyi P; Keilholz U; Kuczyk MA
Aktuelle Urol; 2020 Dec; 51(6):572-581. PubMed ID: 33027832
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine Kinase Inhibitors' Newly Reported Endocrine Side Effect: Pazopanib-Induced Primary Adrenal Insufficiency in a Patient With Metastatic Renal Cell Cancer.
Elshimy G; Gandhi A; Guo R; Correa R
J Investig Med High Impact Case Rep; 2020; 8():2324709620936808. PubMed ID: 32583692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]